العلاج الموضعي من الخط الأول للبهاق المحدود

References

DOI: 10.1111/jdv.19450

• TCIs are first-line treatment in adults and children with limited involvement, especially for lesions in the face, neck and body folds with thin skin (e.g. inguinal, axillary regions).
• A twice-daily application of TCI can be recommended (Radakovic-Fijan et al., 2009).
• The treatment should be prescribed initially for 6 months.
• When effective, prolonged treatment (e.g. up to 12 months or more) can be proposed.
• In adults and children, once-daily application of potent TCS is recommended for patients with limited involvement.
• Most studies used potent to very potent corticosteroids once daily, applied topically for 3–6 months.
• The risk of local side effects (skin atrophy, telangiectasia, hypertrichosis, acneiform eruptions and striae) can be reduced by using an intermittent/alternating treatment scheme (e.g. 2 weeks on 2 weeks off) and will enable longer treatment periods.
• The topical JAK-inhibitor ruxolitinib is now the first treatment approved for the repigmentation of vitiligo.
• TCI monotherapy can induce ≥25% repigmentation in 55.0% of patients and ≥75% repigmentation in 18.1% after 3 months.